Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Breeze Meds vs GoodRx (Foundayo + Zepbound KwikPen)

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.3

Breeze Meds

Best for compounded GLP-1 access with named prescribers and 4-pharmacy network
★★★3.7

Starting at $199/mo

CompoundedSemaglutideTirzepatideAll 50 States
Visit Breeze Meds
8.4

GoodRx (Foundayo + Zepbound KwikPen)

Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
★★★★4.2

Starting at $149/mo

FoundayoZepbound KwikPenBrandSelf-Pay Discount Card
Visit GoodRx (Foundayo + Zepbound KwikPen)

Side-by-Side Comparison

FeatureBreeze MedsGoodRx (Foundayo + Zepbound KwikPen)
Overall Score7.3/108.4/10
Starting Price$199/mo$149/mo
Editorial Rating3.7 ★ /54.2 ★ /5
Features6 features6 features
States Available050
Compounded✓ Yes
Brand Name✓ Yes
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Breeze Meds

Pros

  • Available in all 50 US states
  • LegitScript certified seal displayed in footer
  • Publicly named medical team with NPI numbers: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
  • Four named 503A pharmacy partners: Belmar Pharma Solutions, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx
  • Both injectable and oral formats available for semaglutide and tirzepatide
  • No FDA warning letters or litigation on record as of 2026-04-09

Cons

  • Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Care Bare Rx and Synergy Rx — if you're comparing the three brands, be aware you're comparing three storefronts on top of one underlying operation, not three independent providers
  • Compounded medications are not FDA-approved
  • Compounded vs. brand-name drug sourcing is ambiguously disclosed on the product pages
  • Terms of Service page returns a 404 (Privacy Policy is present) — a procedural transparency gap
  • Insurance acceptance is not clearly disclosed beyond FSA/HSA eligibility

GoodRx (Foundayo + Zepbound KwikPen)

Pros

  • $149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
  • $299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
  • Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
  • No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
  • Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation

Cons

  • Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
  • Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
  • Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
  • Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
  • GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves

Our Verdict

Winner: GoodRx (Foundayo + Zepbound KwikPen)Score: 8.4/10

GoodRx (Foundayo + Zepbound KwikPen) edges out Breeze Meds with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. Breeze Meds remains a solid alternative, especially if you're looking for compounded GLP-1 access with named prescribers and 4-pharmacy network.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.